All News

Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months with anlotinib plus irinotecan.

Oncology Decoded provides the current management of metastatic bladder cancer, recent advancements in systemic therapy, patient selection, and AE mitigation.

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.

Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.

The CD19 t-haNK therapy alone and in combination with rituximab achieved complete responses and no significant toxicities in 2 patients with late-stage WM.

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.

Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.

The novel cancer vaccine plus pembrolizumab missed statistical significance, though it generated a clinically meaningful improvement, in advanced melanoma.

Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.

The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.

Roxadustat’s developers intend to file the full phase 3 protocol for the FDA in the fourth quarter of 2025.

START is the largest early-phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, PhD, MRCPI.

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as in solid tumors and beyond, includes immune therapies.

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.

Preplanned interim results from the phase 3 EPCORE FL-1 trial support the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.

Balancing a career as a pediatric oncologist with leadership responsibilities, Maria C. Velez, MD, shares insights into her passion for the field and ASPHO’s impactful work.